Safety Profiles of Newer Contraceptives presented at meeting of Society of Reproductive Investigation

RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017.  The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.

For more details see the presentation poster here.

 

Posted in

More RSI News

Risk of Myocarditis and Pericarditis

May 11, 2022
RSI logo in white

Using data from the US Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System, RSI investigators collaborated on a study showing increased risks of…

Read News Item

Quinolones and risk of retinal detachment

April 26, 2022
Quinolones

Following previous work on the potential risk of acute liver failure associated with quinolone antibiotics, RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel…

Read News Item

IAI climate change report

April 12, 2022
IAI Climate Change report

The International Aluminium Institute (IAI) recently commissioned Climate Risk Institute (CRI) and Risk Sciences International (RSI) to produce a series of informational tools evaluating and…

Read News Item

Quinolones and risk of acute liver failure

April 12, 2022
Quinolones

Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…

Read News Item